Skip to Content

The 16th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Cancer Research

February 6-8, 2014

Conference Location

Hyatt Regency La Jolla
3777 La Jolla Village Drive 
San Diego, California 

General Information

  • Conference Brochure
  • Conference Agenda
  • Committee and Speakers
  • Registration Information
  • Hotel & Transportation
  • Poster Submission Information
  • San Diego Visitor Information

Program Overview

The field of anti-angiogenic therapy is quite complicated with various results with individual agents in different disease types. In fact, the efficacy of such agents in the advanced setting is different from that of an early stage in the adjuvant setting. In addition to learning more about the efficacy and appropriate use of these agents, it is also important for health care providers to understand new toxicities that have been recognized in association with the use of anti-angiogenic agents.

This symposium will provide a comprehensive overview of the appropriate use of anti-angiogenic therapy in patients with solid malignancies. In addition, this symposium will review the appropriate use of anti-angiogenic agents and allow the learner to recognize toxicity and potential biomarkers.  

The main area of feedback focused on biomarkers and the appropriate use of therapy. This is an inherent challenge as we do not have any biomarkers that are validated. However we will continue
to scan the literature and seek speakers who can address the issue of biomarkers and patient selection. We will also seek speakers and discuss resistance pathways, which overlap with the above issues.

Educational Objectives

After attending the symposium, participants should be able to

  • Summarize available data from clinical trials that support the use of currently available anti-angiogenic agents as monotherapy or in combination with other therapeutic modalities, for appropriate clinical decisions (Knowledge, Competence, Performance, Patient Outcomes);
  • Explain relevant aspects of vascular biology; define angiogenesis and its relevance to the treatment of cancer (Knowledge, Competence);
  • Outline the rationale for the development of anti-angiogenic agents, why angiogenic signaling pathways are targets for inhibition, and how resistance mechanisms function (Knowledge, Competence); 
  • Discuss and apply preclinical and clinical data on emerging anti-angiogenic agents to improve safety, efficacy, and ultimately, quality of patient care (Knowledge, Competence, Performance, Patient Outcomes);
  • Gather highlights on current controversies and emerging strategies in the field, for changes to clinical practice and, if necessary, further discussion or research (Knowledge, Competence, Performance, Patient Outcomes).

Target Audience

This symposium is designed for medical, surgical, and radiation oncologist, pharmacists, other providers of cancer care (Pas, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice.

Educational Methods

• Lectures
• Panel Discussion
• Question & Answer
• Poster Sessions

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category 1 Credit™  or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.


© 2014 The University of Texas MD Anderson Cancer Center